Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database

Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database

<p>Tafamidis emerged as the first FDA-approved drug for treating termed amyloid fibrils. This study aims to analyze adverse events (AEs) related to tafamidis from the second quarter (Q2) of 2019 to the fourth quarter (Q4) of 2023 from the FDA adverse event reporting system (FAERS) database.<...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Min Chen (147733) (author)
مؤلفون آخرون:	Yaping Huang (1662052) (author), Chengjie Ke (18808696) (author), Maohua Chen (479581) (author)
منشور في:	2024
الموضوعات:	Medicine Cell Biology Pharmacology Biotechnology Mental Health Tafamidis FAERS adverse events disproportionality pharmacovigilance
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database
حسب: Xueliang Yi (20768632)
منشور في: (2025)

Data Sheet 1_Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database.docx
حسب: Ye Hu (71531)
منشور في: (2025)

Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database
حسب: Xuyang Cai (19367814)
منشور في: (2025)

Table 1_Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system.pdf
حسب: Sentai Wang (20963168)
منشور في: (2025)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine
حسب: Cheng Zhang (70708)
منشور في: (2024)

Supplementary file 1_Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases.docx
حسب: Yaxing Li (1538230)
منشور في: (2025)

Dementia-related adverse events associated with direct oral anticoagulants use: a real-world, pharmacovigilance study based on the FAERS database
حسب: Hanxu Zhang (8422388)
منشور في: (2025)

Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database
حسب: Xiangyang Le (8769839)
منشور في: (2025)

Table 3_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
حسب: Satoko Watanabe (59124)
منشور في: (2025)

Table 2_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
حسب: Satoko Watanabe (59124)
منشور في: (2025)

Table 4_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
حسب: Satoko Watanabe (59124)
منشور في: (2025)

Table 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
حسب: Satoko Watanabe (59124)
منشور في: (2025)

Data Sheet 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.pdf
حسب: Satoko Watanabe (59124)
منشور في: (2025)

Data Sheet 1_Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system.zip
حسب: Nan Chen (142925)
منشور في: (2025)

Data Sheet 1_Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database.docx
حسب: Peiyang Cao (10808613)
منشور في: (2025)

Table 1_Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis.docx
حسب: Hui Chen (28597)
منشور في: (2025)

Table 2_Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.xlsx
حسب: Yanjun Lu (482204)
منشور في: (2024)

Table 1_Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.xlsx
حسب: Yanjun Lu (482204)
منشور في: (2024)

Table 3_Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.pdf
حسب: Yanjun Lu (482204)
منشور في: (2024)

Table 1_Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).xlsx
حسب: Zhuomiao Lin (14118531)
منشور في: (2025)

Table 2_Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).xlsx
حسب: Zhuomiao Lin (14118531)
منشور في: (2025)

Table 3_Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).xlsx
حسب: Zhuomiao Lin (14118531)
منشور في: (2025)

Table 1_Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.xlsx
حسب: Wensheng Liu (205723)
منشور في: (2025)

Table 2_Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.xlsx
حسب: Wensheng Liu (205723)
منشور في: (2025)

Table 4_Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.xlsx
حسب: Wensheng Liu (205723)
منشور في: (2025)

Table 3_Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.xlsx
حسب: Wensheng Liu (205723)
منشور في: (2025)

Table 1_A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.xlsx
حسب: Ya-Jun Zhang (1625761)
منشور في: (2024)

Table 2_A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.xlsx
حسب: Ya-Jun Zhang (1625761)
منشور في: (2024)

Table 2_Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database.xlsx
حسب: Pan Ding (2485819)
منشور في: (2025)

Table 1_Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database.docx
حسب: Pan Ding (2485819)
منشور في: (2025)

Table 3_Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database.xlsx
حسب: Pan Ding (2485819)
منشور في: (2025)

Data Sheet 1_Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system.docx
حسب: Qian Yu (127062)
منشور في: (2025)

<b>Mining and analysis of reported ARDS population in FAERS database</b>
حسب: Jun'Hua Lai (22510991)
منشور في: (2025)

Assessing the risk of acute kidney injury associated with a four-drug regimen for heart failure: a ten-year real-world pharmacovigilance analysis based on FAERS events
حسب: Sen Lin (182597)
منشور في: (2025)

Table 1_Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database.xlsx
حسب: Liu Yang (23752)
منشور في: (2025)

Table 1_Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database.docx
حسب: Lingli Huang (309787)
منشور في: (2025)

Image 2_Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database.tif
حسب: Lingli Huang (309787)
منشور في: (2025)

Image 1_Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database.tif
حسب: Lingli Huang (309787)
منشور في: (2025)

What does real-world data reveal about cangrelor’s safety? An analysis of FDA adverse event reporting system (FAERS) database
حسب: Zhaojun Wang (523048)
منشور في: (2025)

A real-world pharmacovigilance analysis for agalsidase beta: findings from the FDA adverse event reporting database
حسب: Wen-Long Xie (19842993)
منشور في: (2024)

Cannot write session to /tmp/vufind_sessions/sess_84nhggkdproko0f0v6na2rlna2